Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tenaya Therapeutics (TNYA – Research Report). The associated price target remains the same with $3.00.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight the potential of Tenaya Therapeutics’ TN-201 program. The recent failure of Bristol-Myers Squibb’s Camzyos in the ODYSSEY-HCM trial removes a significant competitor from the landscape, potentially easing patient enrollment for Tenaya’s clinical studies. This development could also reduce future commercial competition, benefiting Tenaya’s market position.
Additionally, the target patient population for Tenaya’s TN-201, particularly those with MYBPC3-related hypertrophic cardiomyopathy, represents a substantial market opportunity. Given these strategic advantages, along with Tenaya’s focus on addressing a significant unmet medical need, Cory Jubinville, PhD sees a promising outlook for the company’s stock, justifying the Buy rating.
In another report released on April 1, Morgan Stanley also maintained a Buy rating on the stock with a $5.00 price target.